Zobrazeno 1 - 10 of 23 pro vyhledávání: '"Paul Baverel"'
2
Akademický článek
Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status
Autor: Paul Baverel, Lorin Roskos, Manasa Tatipalli, Nancy Lee, Paul Stockman, Maria Taboada, Paolo Vicini, Kevin Horgan, Rajesh Narwal
Publikováno v: Clinical and Translational Science, Vol 12, Iss 5, Pp 450-458 (2019)
Tremelimumab, an anti‐cytotoxic T‐lymphocyte antigen‐4 monoclonal antibody that enhances T‐cell activation, was evaluated in a randomized, double‐blind, placebo‐controlled, phase IIb study (NCT01843374) in patients with unresectable malig
Externí odkaz: https://doaj.org/article/b6d5b1ddac5644ac85fd3fb4531ab7e3
Zobrazit plný text záznamu
3
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development
Autor: Ana Ruiz-Garcia, Paul Baverel, Dean Bottino, Michael Dolton, Yan Feng, Ignacio González-García, Jaeyeon Kim, Seth Robey, Indrajeet Singh, David Turner, Shu-Pei Wu, Donghua Yin, Di Zhou, Hao Zhu, Peter Bonate
Publikováno v: Journal of Pharmacokinetics and Pharmacodynamics. 50:147-172
Exposure–response (E–R) analyses are an integral component in the development of oncology products. Characterizing the relationship between drug exposure metrics and response allows the sponsor to use modeling and simulation to address both inter
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::930dfc175ba48c8b30148ee26bbd619d
https://doi.org/10.1007/s10928-023-09850-2
Zobrazit plný text záznamu
7
Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy
Autor: Vincent F. S. Dubois, Stuart Spencer, Vadryn Pierre, Paul Baverel, Helen Moore, Nassim Morsli, Ignacio González-García
Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 3, Pp 230-240 (2021)
CPT: Pharmacometrics & Systems Pharmacology
We developed and evaluated a method for making early predictions of best overall response (BOR) and overall survival at 6 months (OS6) in patients with cancer treated with immunotherapy. This method combines machine learning with modeling of longitud
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1acebe25241822740b4ed19ae8ca321
https://doi.org/10.1002/psp4.12594
Zobrazit plný text záznamu
8
Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status
Autor: Maria Taboada, Nancy Lee, Paolo Vicini, Lorin Roskos, Rajesh Narwal, Manasa Tatipalli, Kevin Horgan, Paul Baverel, Paul K. Stockman
Publikováno v: Clinical and Translational Science, Vol 12, Iss 5, Pp 450-458 (2019)
Clinical and Translational Science
Tremelimumab, an anti‐cytotoxic T‐lymphocyte antigen‐4 monoclonal antibody that enhances T‐cell activation, was evaluated in a randomized, double‐blind, placebo‐controlled, phase IIb study (NCT01843374) in patients with unresectable malig
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b01a2b38a68836cb0f24484c3ac4d09
https://doaj.org/article/b6d5b1ddac5644ac85fd3fb4531ab7e3
Zobrazit plný text záznamu
9
Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total
Autor: Leeron Marshall, Vincent F. S. Dubois, Ignacio González-García, Paul Baverel, John Hood, Paolo Vicini, Nicholas J. White
Publikováno v: Pharmaceutics
Volume 13
Issue 4
Pharmaceutics, Vol 13, Iss 519, p 519 (2021)
A sequential pharmacokinetic (PK) and pharmacodynamic (PD) model was built with Nonlinear Mixed Effects Modelling based on data from a first-in-human trial of a novel biologic, MEDI7836. MEDI7836 is a human immunoglobulin G1 lambda (IgG1λ-YTE) monoc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b359c8219a67ef96ed7f4e6ad24541eb
Zobrazit plný text záznamu
10
Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma
Autor: Lorin Roskos, Alejandro Javier Yovine, Rosalinda Hgp Arends, Nassim Morsli, Ignacio González-García, Xiang Guo, James Xie, Paul Baverel
Publikováno v: Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
The potential for durvalumab, a programmed cell death ligand-1 (PD-L1)-blocking monoclonal antibody, to treat head and neck squamous cell carcinoma (HNSCC) is being evaluated in multiple clinical trials. We assessed circulating proteins at baseline t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99ccf7a3a09f69f3e47187c3a39881e6
https://doi.org/10.1080/2162402x.2021.1898104
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje